Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma

Abstract

To evaluate the National Comprehensive Cancer Network (NCCN) International Prognostic Index (IPI), we analyzed 284 patients treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in our institution in Japan. Their 5-year overall survival (OS) by risk level was 80.7%, 74.8%, 55.4% and 67.5% (P=0.005… (More)
DOI: 10.1016/j.lrr.2016.06.003

Topics

3 Figures and Tables

Cite this paper

@inproceedings{Nakaya2016EnhancedIP, title={Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma}, author={Aya Nakaya and Shinya Fujita and Atsushi Satake and Takahisa Nakanishi and Yoshiko Azuma and Yukie Tsubokura and Masaaki Hotta and Hideaki Yoshimura and Kazuyoshi Ishii and Tomoki Ito and Shosaku Nomura}, booktitle={Leukemia research reports}, year={2016} }